Peptide Targeting Mycobacterium Tuberculosis Toxin-Antitoxin System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Mycobacterium tuberculosis are inadequate due to the emergence of multidrug-resistant strains, and existing antibiotics fail to effectively target the toxin-antitoxin systems, particularly the VapBC family, which plays a crucial role in the extreme incubation period and drug resistance of the bacteria.
Innovation Solution
A peptide is developed that inhibits the binding of the antitoxin protein to specific residues of the Mycobacterium tuberculosis toxin protein, disrupting the toxin-antitoxin complex formation without affecting the toxin's activity, thereby inducing bacterial death.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibiotics are used to treat Mycobacterium tuberculosis, then treatment of susceptible strains is effective, but multidrug-resistant strains cannot be effectively treated
Solution Approach 1:
The invention extracts and targets the toxin-antitoxin system specifically, rather than using broad-spectrum antibiotics. By designing a peptide that selectively binds to the VapBC26 toxin-antitoxin complex, the treatment achieves specificity for tuberculosis bacteria while bypassing the resistance mechanisms that have rendered conventional antibiotics ineffective against multidrug-resistant strains.
Solution Approach 2:
The invention changes the therapeutic parameter from conventional antibiotic targets (cell wall synthesis, protein synthesis, DNA replication) to the toxin-antitoxin system. This parameter change allows the peptide to act on a different biological pathway that is essential for tuberculosis survival but not targeted by existing antibiotics, thereby overcoming multidrug resistance.
2Reliability
If the toxin-antitoxin system is targeted to induce bacterial death, then novel antibiotic activity is achieved, but the complexity of the mechanism increases
Solution Approach 1:
The peptide acts as an intermediary molecule that facilitates the disruption of the toxin-antitoxin complex. By binding to the VapC26 toxin, the peptide prevents the VapB26 antitoxin from neutralizing the toxin, thereby indirectly inducing bacterial death without requiring direct interference with complex bacterial physiological processes.
3Reliability
If the peptide binds to the toxin protein to inhibit complex formation, then bacterial death is induced, but the toxin's native activity may be affected
Solution Approach 1:
The peptide is designed to bind to a specific local region of the toxin protein (the interface region involved in antitoxin binding) rather than affecting the entire toxin structure. This localized binding disrupts the toxin-antitoxin complex formation while preserving the toxin's overall structure and preventing unwanted side effects from broad structural modifications.
Data Source
AI summary
The present invention relates to a peptide targeting a toxin-antitoxin system of Mycobacterium tuberculosis and a use thereof. Specifically, the antibiotic peptide of the present invention inhibits the formation of a toxin-antitoxin complex of Mycobacterium tuberculosis without affecting an active site of the toxin, thereby inducing the death of Mycobacterium tuberculosis by means of a separated toxin. Therefore, the antibiotic peptide can be usefully used as an antibiotic composition against Mycobacterium tuberculosis.